Quotes 5-day view Delayed Nasdaq
2 395 696
1 310 956
3 186 782
Estimated financial data (e) (USD)
Net income 2022
Net Debt 2022
P/E ratio 2022
Net income 2023
Net Debt 2023
P/E ratio 2023
6 462 M
6 462 M
Capi. / Sales 2022
Capi. / Sales 2023
Nbr of Employees
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaboratorsâ€™...
Ratings of Halozyme Therapeutics, Inc.
All news about HALOZYME THERAPEUTICS, INC.
06/15 TRANSCRIPT : Halozyme Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..
06/10 Genmab Seeks $405 Million in New Arbitration With Janssen
06/10 Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen
06/08 Halozyme to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
06/07 Halozyme Therapeutics Launches Testosterone Replacement Therapy Drug Tlando
06/07 Halozyme Announces Commercial Launch of TLANDO™, an Oral Treatment for Testostero..
06/07 Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment fo..
05/26 Goldman Sachs Raises Halozyme Therapeutics' Price Target to $60 From $48, Buy Rating Ke..
05/24 HALOZYME THERAPEUTICS : Completes Antares Pharma Acquisition - Form 8-K
05/24 HALOZYME THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Ac..
05/24 Halozyme Completes Antares Pharma Acquisition
05/23 Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc..
05/12 Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition
05/12 Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
05/11 JMP Securities Raises Halozyme Therapeutics Price Target to $58 From $55, Maintains Mar..
News in other languages on HALOZYME THERAPEUTICS, INC.
Analyst Recommendations on HALOZYME THERAPEUTICS, INC.
Chart HALOZYME THERAPEUTICS, INC.
Technical analysis trends HALOZYME THERAPEUTICS, INC.
Short Term Mid-Term Long Term Trends Neutral Bullish Bullish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target